Nauli Siti E, Prima Putri Vebiona K, Arifianto Habibie, Prameswari Hawani S, Lubis Anggia C, Zulkarnain Edrian, Hasanah Dian Y, Dewi Yamin Paskariatne P, Dewi Triwedya I
Department of Cardiology, Tangerang District Hospital, Tangerang, IDN.
Working Group on Heart Failure and Cardiometabolic Disease, Indonesian Heart Association, West Jakarta, IDN.
Cureus. 2023 Apr 24;15(4):e38086. doi: 10.7759/cureus.38086. eCollection 2023 Apr.
Introduction Heart failure (HF) is a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion. Among HF types, HF with preserved ejection fraction (HFpEF) is the commonest form. However, the diagnosis and management of HFpEF are challenging. In addition, the perception of healthcare professionals (HCPs) towards the diagnosis and management of HFpEF patients differs due to the existing gap between the guidelines and daily clinical practice. Therefore, an online survey was conducted to understand the HCPs' knowledge and practice gaps in the diagnosis, treatment, and management of patients with HFpEF. Methods A total of 160 respondents, i.e., cardiologists, internists, and cardiology residents from different community-based practices and hospitals across Indonesia participated in an online continuing medical education (CME) survey. A questionnaire was formulated to assess awareness, current practice patterns, challenges, and confidence of the HCPs related to the HFpEF. Results HCPs stated that diagnosis of HF is the prime responsibility of cardiologists and general physicians but not of general internists. According to the HCPs, reduction in mortality, reduction in hospitalization, and improved quality of life are the most important goals of HF treatment. The perceived prevalence of HFpEF is estimated to be 30-60% and mortality rates of HFpEF and HF with reduced ejection fraction (HFrEF) are similar. Further, mixed types of responses with different combinations of diagnosis, treatment, and prevention, were obtained when HCPs were asked about the challenges faced in HFpEF. Among the therapies, angiotensin-converting enzyme (ACE) inhibitors, mineralocorticoid receptor antagonists (MRA), beta-blockers, and diuretics are frequently used for the treatment of HF. Conclusion The perception of the HCPs toward the diagnosis and management of HFpEF may affect optimal care. Based on our findings, the cardiologists are well aware of the current situation of HF in Indonesia and treat patients with HFpEF effectively.
引言
心力衰竭(HF)是一种临床综合征,由心脏结构和/或功能异常引起,伴有症状和/或体征,且利钠肽水平升高和/或有肺或体循环充血的客观证据予以证实。在心力衰竭类型中,射血分数保留的心力衰竭(HFpEF)是最常见的形式。然而,HFpEF的诊断和管理具有挑战性。此外,由于指南与日常临床实践之间存在差距,医疗保健专业人员(HCPs)对HFpEF患者的诊断和管理的认知也有所不同。因此,开展了一项在线调查,以了解HCPs在HFpEF患者诊断、治疗和管理方面的知识和实践差距。
方法
共有160名受访者,即来自印度尼西亚不同社区诊所和医院的心脏病专家、内科医生和心脏病学住院医师参加了一项在线继续医学教育(CME)调查。制定了一份问卷,以评估HCPs对HFpEF的认知、当前实践模式、挑战和信心。
结果
HCPs表示,心力衰竭的诊断主要是心脏病专家和普通内科医生的责任,而非普通内科医师的责任。据HCPs称,降低死亡率、减少住院率和改善生活质量是心力衰竭治疗的最重要目标。据估计,HFpEF的患病率为30%-60%,HFpEF和射血分数降低的心力衰竭(HFrEF)的死亡率相似。此外,当询问HCPs在HFpEF中面临的挑战时,得到了不同诊断、治疗和预防组合的混合类型回答。在治疗方法中,血管紧张素转换酶(ACE)抑制剂、盐皮质激素受体拮抗剂(MRA)、β受体阻滞剂和利尿剂常用于治疗心力衰竭。
结论
HCPs对HFpEF诊断和管理的认知可能会影响最佳治疗。根据我们的研究结果,心脏病专家充分了解印度尼西亚心力衰竭的现状,并能有效治疗HFpEF患者。